300942.SHE Shenzhen Bioeasy Biotechnology Co. Ltd.
- Market cap
- CNY 2.30B
- P/E
- -
- P/B
- 2.66x
- ROE
- -4.2%
- Dividend yield
- 0.60%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300942.SHE undervalued?
Graham numberThe Graham number of Shenzhen Bioeasy Biotechnology Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shenzhen Bioeasy Biotechnology Co. Ltd. fundamental analysis
No fundamental analysis for Shenzhen Bioeasy Biotechnology Co. Ltd. yet.
Shenzhen Bioeasy Biotechnology Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food safety testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatment column, certified reference, and quality control. It also provides sp…
Full company profileShenzhen Bioeasy Biotechnology Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shenzhen Bioeasy Biotechnology Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 87.0M | 138M | 205M | 239M | 258M | 598M | 687M | 254M | 224M | 263M | 271M |
| Gross Profit | 64.8M | 104M | 140M | 173M | 182M | 426M | 342M | 96.2M | 156M | 168M | 161M |
| Operating Income | 16.5M | 44.5M | 84.8M | 105M | 75.1M | 268M | 98.1M | -175M | 21.0M | 26.4M | 4.46M |
| EBITDA | 30.6M | 48.5M | 89.2M | 111M | 79.8M | 279M | 111M | -151M | 51.8M | 69.7M | -17.9M |
| Net Income | 23.4M | 39.3M | 73.9M | 92.3M | 65.4M | 237M | 83.0M | -185M | 17.1M | 13.7M | -36.5M |
| EPS | 2.34 | 0.54 | 1.42 | 0.26 | 0.18 | 0.60 | 0.21 | -0.46 | 0.04 | 0.03 | -0.09 |
| Balance Sheet | |||||||||||
| Total Assets | 123M | 174M | 297M | 620M | 653M | 1.15B | 1.28B | 1.36B | 1.46B | 1.52B | 1.46B |
| Total Liabilities | 67.8M | 59.2M | 74.2M | 91.3M | 104M | 206M | 318M | 508M | 587M | 617M | 584M |
| Shareholders' Equity | 55.3M | 115M | 223M | 528M | 549M | 945M | 965M | 849M | 869M | 904M | 866M |
| Cash & Short-term Investments | 69.2M | 99.5M | 189M | 442M | 379M | 682M | 247M | 602M | 596M | 393M | 478M |
| Total Debt | - | - | - | - | 54.1M | 41.1M | 119M | 351M | 468M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 36.3M | 23.6M | 57.9M | 67.2M | 63.8M | 255M | 153M | -37.2M | 34.3M | 66.9M | - |
| Capital Expenditure | 9.03M | 10.8M | 10.5M | 26.3M | 82.8M | 79.5M | 177M | 129M | 174M | 45.9M | 54.2M |
| Free Cash Flow | 27.3M | 12.8M | 47.4M | 41.0M | -19.0M | 176M | -24.3M | -166M | -140M | 21.0M | -80.6M |
| Ratios | |||||||||||
| ROE | 42.4% | 34.3% | 33.2% | 17.5% | 11.9% | 25.0% | 8.6% | -21.8% | 2.0% | 1.5% | -4.2% |
| ROA | 19.0% | 22.6% | 24.9% | 14.9% | 10.0% | 20.5% | 6.5% | -13.6% | 1.2% | 0.9% | -2.5% |
| Net Profit Margin | 26.9% | 28.5% | 36.1% | 38.6% | 25.3% | 39.6% | 12.1% | -72.8% | 7.6% | 5.2% | -13.5% |
| Debt to Equity | - | - | - | - | 0.10x | 0.04x | 0.12x | 0.41x | 0.54x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shenzhen Bioeasy Biotechnology Co. Ltd. dividends
- Dividend yield
- 0.60%
- Forward dividend
- 0.02 CNY
- Payout ratio
- 100.8%
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 13.9M | 0.03 | 100.8% |
| 2024 | CNY 5.34M | 0.01 | 31.2% |
| 2023 | CNY 12.9M | 0.03 | - |
| 2022 | CNY 99.8M | 0.25 | 120.3% |
| 2021 | CNY 18.0M | 0.05 | 7.6% |
| 2020 | CNY 45.0M | 0.12 | 68.8% |
| 2019 | CNY 7.00M | 0.02 | 7.6% |
| 2018 | CNY 28.0M | 0.54 | 37.9% |
| 2017 | CNY 28.0M | 0.38 | 71.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shenzhen Bioeasy Biotechnology Co. Ltd.
- Insiders 63.16%
- Institutions 1.68%
- Public & others 35.16%
- Shares outstanding 405M
- Free float 150M
Shenzhen Bioeasy Biotechnology Co. Ltd. company profile
- Company name
- Shenzhen Bioeasy Biotechnology Co. Ltd.
- Ticker
- 300942.SHE
- ISIN
- CNE100004C78
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 542
- Fiscal year end
- December
- Address
- A101, Building 2, Shenzhen, China, 518126
- Phone
- 86 755 2794 8546
- Website
- bioeasy.com
About Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food safety testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatment column, certified reference, and quality control. It also provides specialized solutions, which include multi-mode precision detection, project plan for specialized equipment, AI-powered fully automated grain comprehensive testing workstation, digital food safety automatic detection, rapid testing laboratory, smart supervision, and comprehensive solution for rapid testing. In addition, the company offers software platforms, such as smart grain depot, traceability, orchard, datian, tea garden, and park project, as well as digital village project and agricultural and rural data projects. Its products are used in dairy, cereal and feed, fruit and vegetable, meat and seafood, honey and egg, laboratory, animal health, and other industries. The company was founded in 2007 and is headquartered in Shenzhen, China.
Shenzhen Bioeasy Biotechnology Co. Ltd. management
5- Mr. Zhaoli XiaoChairman & GM · born 1974
- Mr. Guangsheng WangFinancial Director · born 1980
- Ms. Wentian LiDeputy GM, Secretary & Non-Independent Director · born 1992
- Mr. Jin Long ZhangDeputy General Manager · born 1976
- Rui Jie ZhangAccounting Supervisor